REGULATORY MECHANISM OF RANKL GENE EXPRESSION
REGULATORY MECHANISM OF RANKL GENE EXPRESSION
批准号:
14570188
负责人:
KITAZAWA Riko
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Osteoclast differentiation factor (RANKL) is requisite for the formation and maintenance of osteoclasts from hematopoietic precursors. To clarify the mechanism of RANKL gene expression and osteoclastogenesis, mouse and human RANKL gene promoters were characterized. Both human and mouse RANKL gene promoter shares the common structure, inverted-TATA and CAAT boxes, Runx2/Cbfa-1 binding sites and vitamin D responsive element (VDRE). To elucidate the molecular mechanism of osteolytic bone metastasis, we assessed RANKL gene expression and osteoclastogenesis in osteolytic lesions of mouse experimental model and human bone specimen taken at the autopsy. In both mouse and human osteolytic lesion due to cancer metastasis, RANKL expression was observed on the stromal/osteoblastic cells close to the cancer cell nests. In the mouse model, PTHrP-producing tumor generated osteolytic lesion, whereas non-producing tumor rarely caused RANKL expression and induction of osteoclasts. We further analyzed the effects of PTHrP on RANKL gene transcription. By transient transfection studies using deletion constructs of mouse and human RANKL gene promoter, PTHrP upregulated the transcriptional activity through c-AMP responsive element (CRE) located close to VDRE in both mouse and human. EMSA showed specific protein DNA binding, and the supershift with anti-CREB1 and -ATF2 antibodies. Thus PTHrP induces osteoclastic bone resorption through the RANKL expression on stromal/osteoblastic cells, affording a bone microenvironment conducive to the survival of PTHrP-producing cancer cells.We have presented our data at various international as well as domestic meeting, and published scientific papers for academic journals.
期刊论文(75)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Srivastava S: "Receptor Activator of NF-kB Ligand (RANKL) Induction via Jak2 and Stat 5a in Mammary Epithelial Cells"J Biol Chem. 278. 46171-46178 (2003)
Srivastava S:“乳腺上皮细胞中通过 Jak2 和 Stat 5a 诱导 NF-kB 配体 (RANKL) 的受体激活剂”J Biol Chem。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kitazawa R, Kitazawa S.: "Vitamin D3 augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter."Biochem Biophys Res Com. 290. 650-655 (2002)
Kitazawa R、Kitazawa S.:“维生素 D3 通过小鼠 RANKL 基因启动子的维生素 D 响应元件增强破骨细胞生成。”Biochem Biophys Res Com。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kondo T, Kitazawa R, Maeda S, Kitazawa S.: "Myxoid leiomyosarcoma of the uterus."Shindan Byori. 19. 247-248 (2002)
Kondo T、Kitazawa R、Maeda S、Kitazawa S.:“子宫粘液样平滑肌肉瘤。”Shindan Byori。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kitazawa S, Kitazawa R.: "Epigenetic control of mouse receptor activator of NFkB ligand gene expression"BBRC. 293・1. 126-131 (2002)
Kitazawa S,Kitazawa R.:“NFkB配体基因表达的小鼠受体激活剂的表观遗传控制” BBRC 293·1(2002)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Darwanto A, Kitazawa R, Maeda A, Kitazawa S.: "MeCP2 and promoter methylation cooperatively regulate E-cadherin gene expression in colorectal carcinoma."Cancer Sci. 94. 442-447 (2003)
Darwanto A、Kitazawa R、Maeda A、Kitazawa S.:“MeCP2 和启动子甲基化协同调节结直肠癌中的 E-钙粘蛋白基因表达。”Cancer Sci。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 38 条
Regulatory Mechanism of RANK Gene Expression during Osteoclastic Differentiation of Bone Marrow Macrophage/Monocyte Lineage
-
批准号:21590419
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2009
-
负责人:KITAZAWA Riko
-
依托单位:
Analysis of transcriptional regulation of RANK gene and osteoclastic differentiation in bone marrow microenvironment
-
批准号:18590372
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.42万
-
财政年份:2006
-
负责人:KITAZAWA Riko
-
依托单位:
ROLE OF RANKL IN OSTEOLYTIC BONE METASTASIS
-
批准号:16590313
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.11万
-
财政年份:2004
-
负责人:KITAZAWA Riko
-
依托单位:
ANALYSIS OF THE GENE PROMOTERS OF MOUSE OSTEOCLAST DIFFERENTIATION FCTOR (RANKL)
-
批准号:12670204
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:2000
-
负责人:KITAZAWA Riko
-
依托单位:
ANALYSIS OF THE HUMAN α6 INTEGRIN PROMOTER
-
批准号:10670206
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.86万
-
财政年份:1998
-
负责人:KITAZAWA Riko
-
依托单位:
A STUDY OF GENES DIFFERENTIALLY EXPRESSED BY OSTEOCLASTOGENIC MOUSE STROMAL CELLS
-
批准号:09557021
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$5.63万
-
财政年份:1997
-
负责人:KITAZAWA Riko
-
依托单位:
A STUDY OF THE REGULATORY MECHANISM OF CYTOKINES ON OSTEOCLASTIC BONE RESORPTION IN POSTMENOPAUSAL OSTEOPOROSIS
-
批准号:08670250
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1996
-
负责人:KITAZAWA Riko
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于RANKL/RANK/OPG通路观察补肾活血方干预半月板白-白区撕裂后软骨下骨的研究
-
批准号:2026JJ81068
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:章俊
-
依托单位:
基于“阴消阳长”理论从RANKL/RANK通路探讨阳和汤调控骨转移乳腺癌免疫微环境增敏免疫的机制研究
-
批准号:2026JJ50610
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:毛丹
-
依托单位:
单核巨噬细胞通过RANK/RANKL/OPG 信号通路调控小鼠P3趾尖骨关节再生的机制研究
-
批准号:JCZRYB202500176
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
RANKL-NFATc1-E-NPP4通路促进破骨细胞嘌呤代谢加速绝经后骨质疏松骨量流失的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:禹宝庆
-
依托单位:
基于网络药理学技术及OPG/RANKL/RNAK信号通路探讨壮骨方防治假体无菌性松动机制研究
-
批准号:JCZRLH202501024
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
OPG-RANKL-RANK轴调控NLRP3炎症小体介导DA神经元变性的分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:陈祥
-
依托单位:
CD8+T细胞通过RANKL-RANK轴和小胶质细胞相互作用重塑脊髓损伤免疫微环境影响干细胞疗效的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:梁仟
-
依托单位:
靶向骨转移68Ga/177Lu-RANKL抑制剂诊疗一体化放射性药物研究
-
批准号:
-
项目类别:面上项目
-
资助金额:48万元
-
批准年份:2024
-
负责人:陈跃
-
依托单位:
三七素调控RANKL信号的干细胞联合创新疗法治疗骨质疏松的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:仓定伟
-
依托单位:
基于OPG/RANK/RANKL信号通路研究异补骨脂素调控炎症抗骨质疏松的作用机制
-
批准号:2024Y9519
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:陈长贤
-
依托单位: